These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 9025778

  • 1. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine.
    Dorie MJ, Brown JM.
    Cancer Chemother Pharmacol; 1997; 39(4):361-6. PubMed ID: 9025778
    [Abstract] [Full Text] [Related]

  • 2. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
    Papadopoulou MV, Ji M, Bloomer WD.
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):160-8. PubMed ID: 11561782
    [Abstract] [Full Text] [Related]

  • 3. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer.
    Wouters BG, Wang LH, Brown JM.
    Ann Oncol; 1999 Aug; 10 Suppl 5():S29-33. PubMed ID: 10582136
    [Abstract] [Full Text] [Related]

  • 4. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.
    Siim BG, Menke DR, Dorie MJ, Brown JM.
    Cancer Res; 1997 Jul 15; 57(14):2922-8. PubMed ID: 9230202
    [Abstract] [Full Text] [Related]

  • 5. Usefulness of tirapazamine as a combined agent in chemoradiation and thermo-chemoradiation therapy at mild temperatures: reference to the effect on intratumor quiescent cells.
    Masunaga SI, Ono K, Suzuki M, Kinashi Y, Takagaki M, Hori H, Kasai S, Nagasawa H, Uto Y.
    Jpn J Cancer Res; 2000 May 15; 91(5):566-72. PubMed ID: 10835503
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
    Xiao Y, Li JD, Shi HL, Liu JH, Feng YL, Li MD.
    Ai Zheng; 2007 Apr 15; 26(4):386-9. PubMed ID: 17430657
    [Abstract] [Full Text] [Related]

  • 8. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D.
    Oncogene; 1999 Apr 01; 18(13):2241-51. PubMed ID: 10327070
    [Abstract] [Full Text] [Related]

  • 9. Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo.
    Papadopoulou MV, Ji X, Bloomer WD.
    J Exp Ther Oncol; 2006 Apr 01; 5(4):261-72. PubMed ID: 17024967
    [Abstract] [Full Text] [Related]

  • 10. Tirapazamine: laboratory data relevant to clinical activity.
    Brown JM, Wang LH.
    Anticancer Drug Des; 1998 Sep 01; 13(6):529-39. PubMed ID: 9755717
    [Abstract] [Full Text] [Related]

  • 11. Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Bloomer WD.
    Oncol Res; 2002 Sep 01; 13(1):47-54. PubMed ID: 12201674
    [Abstract] [Full Text] [Related]

  • 12. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
    Jounaidi Y, Waxman DJ.
    Cancer Res; 2000 Jul 15; 60(14):3761-9. PubMed ID: 10919648
    [Abstract] [Full Text] [Related]

  • 13. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin.
    Dorie MJ, Brown JM.
    Cancer Res; 1993 Oct 01; 53(19):4633-6. PubMed ID: 8402639
    [Abstract] [Full Text] [Related]

  • 14. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
    Hay MP, Gamage SA, Kovacs MS, Pruijn FB, Anderson RF, Patterson AV, Wilson WR, Brown JM, Denny WA.
    J Med Chem; 2003 Jan 02; 46(1):169-82. PubMed ID: 12502371
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine.
    Papadopoulou MV, Ji M, Ji X, Bloomer WD.
    Cancer Chemother Pharmacol; 2002 Oct 02; 50(4):291-8. PubMed ID: 12357303
    [Abstract] [Full Text] [Related]

  • 16. Combined effects of tirapazamine and mild hyperthermia on anti-angiogenic agent (TNP-470) treated tumors-reference to the effect on intratumor quiescent cells.
    Masunaga S, Ono K, Nishimura Y, Kanamori S, Saga T, Suzuki M, Kinashi Y, Takagaki M, Kasai S, Nagasawa H, Uto Y, Hori H.
    Int J Radiat Oncol Biol Phys; 2000 Jun 01; 47(3):799-807. PubMed ID: 10837967
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the potential of hexamethylenetetramine, compared with tirapazamine, as a combined agent with {gamma}-irradiation and cisplatin treatment in vivo.
    Masunaga S, Tano K, Watanabe M, Kashino G, Suzuki M, Kinashi Y, Ono K, Nakamura J.
    Br J Radiol; 2009 May 01; 82(977):392-400. PubMed ID: 19153181
    [Abstract] [Full Text] [Related]

  • 18. [Evaluation of the toxicity of tirapazamine plus cisplatin in a mouse tumor model].
    Adam M, Ottenjann S, Künzel G, Busch R, Erhardt W, Nieder C, Molls M.
    Strahlenther Onkol; 2006 Apr 01; 182(4):231-9. PubMed ID: 16622625
    [Abstract] [Full Text] [Related]

  • 19. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin.
    Goldberg Z, Evans J, Birrell G, Brown JM.
    Int J Radiat Oncol Biol Phys; 2001 Jan 01; 49(1):175-82. PubMed ID: 11163512
    [Abstract] [Full Text] [Related]

  • 20. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
    Dorie MJ, Kovacs MS, Gabalski EC, Adam M, Le QT, Bloch DA, Pinto HA, Terris DJ, Brown JM.
    Neoplasia; 1999 Nov 01; 1(5):461-7. PubMed ID: 10933062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.